Compare 10X Genomics Inc (TXG) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? 10X Genomics Inc trades at $58.6 (market cap $7.64B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.4. The key difference: 10X Genomics Inc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| TXG | YMAG | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $58.57 | $15.98 |
52-Week Low | $11.34 | $10.76 |
Enterprise Value | $7.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
YMAG trades at $11.58, up 0.87% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.07 to $0.40 per share. News highlights ongoing distribution announcements and analysis of its option income strategy, though key financial ratios are not provided in the data.
The outlook hinges on YMAG's ability to sustain high distributions through its option strategy, but earnings volatility in underlying holdings poses a risk to NAV stability. Investor sentiment is mixed, with some analysts viewing it as a tactical buy in rangebound markets, while others caution on compounded decay across its seven underlying ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
